New drug cocktail aims to tame metastatic prostate cancer
NCT ID NCT05367440
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called AZD5305 combined with standard hormone therapies in 174 men with metastatic prostate cancer. The goal is to see if the combination is safe and can help control the disease. Participants take daily pills, and researchers monitor side effects and how well the drugs work.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AZD5305 (a targeted cancer drug) combined with hormone therapies (enzalutamide, abiraterone acetate, darolutamide, or apalutamide)
What this could lead to
If successful, this could point toward a new combination treatment that helps control metastatic prostate cancer for longer.
What could go wrong
This is an early-phase trial with only 174 participants, so results may not apply to all patients. The drug combinations could cause side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Detroit, Michigan, 48201, United States
-
Research Site
Detroit, Michigan, 48202, United States
-
Research Site
Syracuse, New York, 13210, United States
-
Research Site
Myrtle Beach, South Carolina, 29572, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
Houston, Texas, 77094, United States
-
Research Site
Camperdown, 2050, Australia
-
Research Site
Darlinghurst, 2010, Australia
-
Research Site
East Melbourne, 3002, Australia
-
Research Site
Heidelberg, 3084, Australia
-
Research Site
Melbourne, 3004, Australia
-
Research Site
St Leonards, 2065, Australia
-
Research Site
Candiolo, 10060, Italy
-
Research Site
Milan, 20133, Italy
-
Research Site
Orbassano, 10043, Italy
-
Research Site
Padova, 35128, Italy
-
Research Site
Cambridge, CB2 0QQ, United Kingdom
-
Research Site
Glasgow, G12 0YN, United Kingdom
-
Research Site
Manchester, M20 4BX, United Kingdom
-
Research Site
Plymouth, PL6 8DH, United Kingdom